The Oncology Grand Rounds series is designed to place original reports published in the Journal into clinical context. A case presentation is followed by a description of diagnostic and management challenges, a review of the relevant literature, and a summary of the authors' suggested management approaches. The goal of this series is to help readers better understand how to apply the results of key studies, including those published in Journal of Clinical Oncology, to patients seen in their own clinical practice.
A 55-year-old postmenopausal woman, gravida 5 para 5, with past medical history significant for hypertension, presented to the emergency department with profuse vaginal bleeding and a hemoglobin level of 9 g/dL. The biopsy from an irregular 6-cm cervical mass was consistent with moderately differentiated cervical squamous cell carcinoma. The physical examination did not reveal vaginal or parametrial extension of the tumor. Pelvic magnetic resonance imaging disclosed the known carcinoma, as well as a 9.2 3 7.7 3 6.7 cm anterior uterine fibroid (Fig 1) . A staging positron emission tomography scan was negative for metastatic disease. After blood transfusion and vaginal packing, the patient was referred to discuss the immediate management of her newly diagnosed bleeding bulky cervical cancer. In the absence of parametrial or vaginal extension and in the absence of lymph node metastasis (both on clinical examination and imaging), she was classified as having International Federation of Gynecology and Obstetrics stage IB2 disease.
CHALLENGES IN DIAGNOSIS AND MANAGEMENT
Despite efficient screening 1 and vaccination, 2 cervical squamous cell carcinoma (CSCC) is the fourth most common cancer in women worldwide, 3 annually affecting . 500,000 patients. 4 Most CSCCs (85%) occur in developing countries with limited access to screening, diagnostic, or treatment capabilities, accounting for the higher propensity for advanced stage at diagnosis and higher mortality rates when compared with early-stage tumors found through screening. 5 In this advanced-stage patient population presenting with tumors . 4 cm with or without extension into the parametrium, pelvic side walls, or lower third of the vagina and/or with lymph node metastasis, the standard of care is combined chemoradiotherapy followed by brachytherapy, 6 which yields a 5-year survival rate of 66% to 87% for stage IB, 61% to 74% for stage II, and 47% to 71% for stage III disease. 7 In low-resource settings, the simple execution of this treatment regimen may represent a challenge as a result of limited financial support and lack of chemotherapy infusion and radiation delivery systems such as linear accelerators and brachytherapy machines. 8 However, among low-risk early-stage CSCCs (International Federation of Gynecology and Obstetrics [FIGO] ; stage IB to IIA), treatment failure persists, with failure rates are between 10% and 30% with either definitive radiotherapy (RT) and concurrent chemoradiotherapy (CCRT) or radical hysterectomy (with or without adjuvant RT or CCRT). 9 Neoadjuvant chemotherapy (NACT) offers early systemic targeting of subclinical distant disease and assessment of tumor response to chemotherapy regimen and may permit radical hysterectomy with negative surgical margins while avoiding RT toxicity and compensating for the paucity of RT machines or expertise. Although NACT may provide a viable option for many patients, the evidence supporting its use is still limited. 10 
SUMMARY OF RELEVANT LITERATURE
In many disease sites, the theoretical advantages of NACT, whether delivered before radical surgery or radical RT, were demonstrated in the clinical setting through improvement of survival secondary to reduction of distant failure rates, 11-16 decrease in local failure 11, 16, 17 (secondary to higher resectability with negative surgical margins or improved radiation efficiency through better oxygenation and lower exposure to surrounding normal tissue as a result of a shrinking tumor volume), and/or improvement in organ preservation rates.
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In cervical cancer, NACT yields complete clinical and pathologic response rates ranging from 7.5% to 39% and 11% to 20%, respectively.
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These impressive response rates may result in a reduction in the need for adjuvant RT from 53% to 34%. 21 The potential of NACT to reduce the need for either radical or adjuvant RT 22 is significant, especially in regions with limited external-beam RT and/or brachytherapy capabilities. In addition to avoiding RT toxicity, NACT may allow for fertility preservation without compromising oncologic outcomes. 23, 24 However, in cervical cancer, NACT has not routinely translated into a survival benefit compared with either surgery alone or definitive RT. 21 Several factors could explain this finding. First, the accuracy of clinical staging workup with inclusion of magnetic resonance imaging (MRI) and/or positron emission tomography (PET) was not mandatory in most NACT studies, which included patients with a variety of clinically staged cervical cancers (stages IB to IIIB). 10 In addition to the potential for imbalance bias in the treatment arms, this discrepancy of clinical staging versus surgical or pathologic staging in a primary surgical versus neoadjuvant therapy approach study design can only be accentuated in a cervical cancer disease site predominantly relying on FIGO. 25, 26 Second, the majority of women do not have a clinically meaningful response to NACT, and chemotherapy treatment might actually delay effective local therapy. 20 Such concerns may account for outcomes in the Gynecologic Oncology Group 141 trial comparing NACT followed by radical hysterectomy and pelvic or para-aortic lymph node dissection versus radical surgery alone in 288 patients with stage IB2 disease. In the NACT arm, positive pelvic node disease, positive para-aortic lymph node disease, and parametrial extension were present in 32%, 10%, and 17% of patients, respectively, essentially negating the benefit of the addition of NACT to radical surgery in all end points, despite a 52% overall response rate. 27 Moreover, meta-analyses of studies comparing a local modality (whether surgery or RT alone) with or without NACT reported inconsistency in its benefit. 10, 28 These results were unchanged even after restricting the analysis to stage IB to IIA disease. 21 The interpretation of these studies is further complicated by the fact that a significant proportion of patients needed adjuvant RT and that, when RT was the comparator arm, it was delivered either without chemotherapy or with suboptimal cumulative chemotherapy dose 29 and/or with suboptimal brachytherapy dose. [30] [31] [32] These reports underscore the importance of chemotherapy regimen, dose density, and duration in determining NACT benefit 20 and make it unsurprising that a recent study randomly assigning patients with stage IB2 to IIA disease to NACT plus surgery versus radical CCRT did not report a significant benefit with NACT. 33 Given the limited data on long-term effectiveness of NACT, the European Organization for Research and Treatment of Cancer 55994 study, which addressed the importance of cisplatin cumulative dose, could provide meaningful insights. 34 This later phase III study completed accrual of more than 600 patients with stage IB2 to IIB cervical cancer and randomly assigned patients to NACT followed by surgery versus CCRT. The primary end point survival results are expected in 2019, with preliminary results from the trial noting a 49% imagebased complete response rate with acceptable short-term toxicity. 35 Finally, the synergistic tumoricidal effect of CCRT with its established survival benefit 36 and recent studies showing additional benefit of adjuvant chemotherapy 37-39 raise questions about the exact role of NACT without concurrent RT in the cervical cancer management paradigm and about whether the timing of chemotherapy (adjuvant v neoadjuvant) is of significant importance. If the aim of NACT is to improve resectability with negative surgical margins, neoadjuvant chemoradiotherapy may provide a more efficacious approach. For example, the complete pathologic response rates in hysterectomy specimens was 52% after CCRT in the Gynecologic Oncology Group 123 trial with an acceptable toxicity profile. 40 Neoadjuvant chemoradiotherapy can also provide a viable alternative in regions without accessibility to brachytherapy expertise without detrimental oncologic outcomes, as shown in the study by Cetina et al. 41 After initial treatment of 50.4 Gy of external-beam RT with concurrent cisplatin and gemcitabine, this study randomly assigned 211 patients with stage IB to II cervical cancer to brachytherapy or hysterectomy. Although the pathologic complete response rate was 72% in the surgically treated cohort, there was no difference in progression-free and overall survival between the surgery and brachytherapy arms. 41 In contrast to CSCC, cervical adenocarcinoma is associated with a worse prognosis, 42-44 higher distant metastasis rate, 44 and more RT resistance. 45, 46 For, these reasons, the surgical approach is preferred to induction chemoradiotherapy in patients with cervical adenocarcinoma, 46 unless neoadjuvant treatment is warranted to permit easier surgical resection, especially in node-negative cervical disease. 
SUGGESTED APPROACHES TO MANAGEMENT
NACT will remain a viable option even if the awaited phase III studies do not reveal significant beneficial effect. The availability of RT or brachytherapy expertise, disease stage at presentation, fertility-sparing prospects, superiority for the surgical approach, and patients' comorbidity profile and preference will dictate the incorporation of NACT, and even if it is not featured in current management guidelines, 48 proper selection of patients for this approach will be the main factor determining its therapeutic advantage. 10 Typically, accurate staging using PET and MRI can offer more insight and preferably should be adopted in this setting.
49,50 A multidisciplinary approach would provide the best decision based on the patient's presentation and preferences. If NACT is deemed beneficial, a dose-dense platinum doublet chemotherapy regimen cycled every 2 weeks is initiated, with MRI-based assessment planned before the third cycle. 51, 52 If , 20% reduction in tumor size is detected, chemotherapy resistance should be suspected and the third NACT cycle should be aborted because of concern about delaying definitive treatment or compromising its efficiency secondary to NACT toxicity. If good response is observed, the third cycle should be delivered with trachelectomy (in case of fertility preservation) or hysterectomy planned in 4 to 6 weeks from the last chemotherapy cycle. In the presence of intermediate-or high-risk pathologic factors, adjuvant chemotherapy and/or RT are strongly considered based on the toxicity profile and pathologic response rate at surgery. 39,53 Neoadjuvant chemoradiotherapy can compensate for the low response rate observed after two cycles of NACT and can be considered in certain scenarios where surgery is strongly favored as a result of either concomitant uterine pathology or absence of brachytherapy expertise (Fig 2) . 41 In contrast, RT dose escalation is considered in the presence of genomic biomarkers predicting tumor resistance, thus permitting a tailored incorporation of different modalities in the management of cervical cancer. 54, 55 
CLINICAL DISCUSSION
In the patient introduced earlier, the low hemoglobin level precluded immediate start of NACT, despite preference for the surgical option to treat the CSCC and the symptomatic uterine fibroid. After three fractions of external-beam RT, the bleeding stopped, and after blood transfusion, the patient started chemoradiotherapy with weekly cisplatin 40 mg/m 2 and 45 Gy of RT in 25 fractions as preoperative therapy, in the hope of achieving a good response to permit subsequent hysterectomy, extrapolating from the study by Keys et al. 40 At week 5, the cervical tumor was 4.5 cm in size, and although the original plan had been for surgery after chemoradiotherapy, the patient declined any surgical intervention and was lost to follow-up for 4 weeks. The patient subsequently returned to the clinic but still refused to consider surgical options. She did agree to brachytherapy, and to cover all disease extent while avoiding excessive overall treatment time, interstitial brachytherapy was used (Fig 3) to treat the cervical high-risk clinical target volume. We delivered two fractions per day for a total of 27.5 Gy in five fractions while maintaining rectal, bladder, and sigmoid dose constraints within acceptable limits. The cumulative dose, which covered 90% of the target volume, accounting for different dose per fraction, was 82 Gy. The patient presented to her 6-month followup, and the PET scan performed at this time did not reveal any evidence of active disease, although she did have the residual fibroid.
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